Research & Development
Hospital Acquired Infection
Magnolia Medical Technologies publishes survey report on hospitalization risks
The greatest concern about hospitalization among the 1,002 adults in the U.S. surveyed was the high cost, which outpaced concerns about antimicrobial-resistant bacterial infections, sepsis, hospital-acquired infections, and other risks.
July 26, 2023
Researchers find that prompt C. difficile testing could reduce hospital infection spread, morbidity
Hospital policies allowing nurses to independently initiate testing for the bacterium C. difficile could reduce infection spread and associated morbidity.
May 11, 2023
Antibiotic susceptibility test in study reveals current antibiotics may cure superbugs
The test revealed that some of the commercial, FDA-approved antibiotics can treat drug-resistant superbug infections.
May 1, 2023
Researchers find hidden bacteria that pose antimicrobial resistance risk to hospital patients
Researchers have found that carriers of specific hidden bacteria have a 14% chance of developing an antibiotic-resistant infection within 30 days of hospitalization.
January 31, 2023
Sentinel creates coronavirus test, adds more PCR tests
The company's Stat-NAT COVID-19 assay is a freeze-dried, ready-to-use, real-time polymerase chain reaction (PCR) mix that can detect the presence of the SARS-CoV-2 virus, which causes COVID-19, in human respiratory tract specimens in about 90 minutes.
March 12, 2020
NeuMoDx and Sentinel partner on PCR assays
New molecular diagnostics will be developed in a range of areas, including for use in post-transplant infections, parasitic and hospital-acquired infections, and respiratory infections. The collaborative work will incorporate Sentinel's Stat-NAT technology, which the companies said was designed to stabilize the activity of the PCR mix to boost shelf life, among other advantages.
December 9, 2019
GNA Biosolutions secures $13.5M in new funding round
GNA said it plans to use the funds to advance the development of its point-of-care molecular diagnostic platform as well as help bring it to the clinic -- first in the European Union and then in the U.S. market. The platform can support the creation of simple, cost-effective molecular diagnostic tests and has already facilitated the production of more than 30 internal assays for hospital-acquired infections and tuberculosis, among other diseases, according to the firm.
August 4, 2019
Page 1 of 1